Oncternal Therapeutics Receives FDA Study May Proceed Letter For ONCT-534, Its Novel Dual-Action Androgen Receptor Inhibitor, For The Treatment Of Patients With Advanced Prostate Cancer
Portfolio Pulse from Benzinga Newsdesk
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) has received a Study May Proceed letter from the FDA for a Phase 1/2 dose escalation study of ONCT-534, a novel dual-action androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer. The company expects to report preliminary data in the first half of 2024.
August 04, 2023 | 2:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oncternal Therapeutics has received FDA approval to proceed with a Phase 1/2 study of ONCT-534. This could potentially open up a new treatment alternative for patients with advanced prostate cancer.
The FDA's approval to proceed with the study of ONCT-534 is a significant milestone for Oncternal Therapeutics. If the study is successful, it could potentially lead to a new treatment alternative for patients with advanced prostate cancer, which would likely have a positive impact on the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100